Triptolide and its pro-drug Minnelide target high-risk MYC amplified medulloblastoma in preclinical models.
Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, Shahani P, Peterson K, Turos-Cabal M, Vieira ME, Wynn DT, Howell AJ, Yang F, Ban Y, McCrea HJ, Zindy F, Danis E, Vibhakar R, Jermakowicz A, Martin V, Coss CC, Harris BT, de Cubas A, Chen XS, Barnoud T, Roussel MF, Ayad NG, Robbins DJ.
Rodriguez-Blanco J, et al. Among authors: chen xs.
J Clin Invest. 2024 Jun 11:e171136. doi: 10.1172/JCI171136. Online ahead of print.
J Clin Invest. 2024.
PMID: 38885332